Benson Viscometers is developing a novel device that can determine the clotting profile of a blood sample. Furthermore, the company also aims to develop the point-of-care capabilities of this device.
Coagulopathy is one of the most preventable causes of death following trauma. It is present at the time of admission to the accident and emergency (A&E) department in 25–35% of trauma patients, and has been implicated as the cause of almost half of haemorrhagic deaths in this group. These patients are associated with higher transfusion requirements, as well as longer stays in intensive care and in hospital generally. In comparison to patients who do not have a coagulopathy, those with it have a three- to four-fold greater risk of mortality, and up to eight times higher mortality within the initial 24 hours of injury.
The correct treatment within the 'golden' first hour following trauma greatly reduces the demand for blood products and also reduces mortality and recovery time. However, blood analysis to ensure correct blood component therapy currently can only be undertaken once the patient arrives at hospital.
Mobile monitoring
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.